Form 4: Cargo Therapeutics Director Acquires Stock Options

Abraham Bassan, a director of Cargo Therapeutics, acquired stock options for 23,742 shares on June 4, 2024.

Summary

• Abraham Bassan, a director of Cargo Therapeutics, acquired stock options on June 4, 2024.
• The options grant the right to buy 23,742 shares of common stock at an exercise price of $19.17 per share.
• The options vest on the earlier of June 4, 2025, or the next Annual Meeting following June 4, 2024, contingent upon continued service to the Issuer.
• The options expire on June 3, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition. It can be seen as slightly positive as it indicates a director's belief in the company's future.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates